

TRIENTINE HYDROCHLORIDE- trientine capsule, gelatin coated
Amneal Pharmaceuticals NY LLC

Trientine Hydrochloride Capsules, USP

Rx only

DESCRIPTION

Trientine hydrochloride, USP is *N,N'*-bis (2-aminoethyl)-1,2-ethanediamine dihydrochloride. It is a white to pale yellow crystalline hygroscopic powder. It is freely soluble in water, soluble in methanol, slightly soluble in ethanol, and insoluble in chloroform and ether.

The empirical formula is $C_6H_{18}N_4 \cdot 2HCl$ with a molecular weight of 219.2. The structural formula is:
 $NH_2(CH_2)_2NH(CH_2)_2NH(CH_2)_2NH_2 \cdot 2HCl$

Trientine hydrochloride (HCl), USP is a chelating compound for removal of excess copper from the body. Each trientine HCl capsule, USP for oral administration contains 250 mg of trientine HCl, USP with the following inactive ingredient: stearic acid. The hard gelatin capsule shells contain the following inactive ingredients: black iron oxide, gelatin, red iron oxide, titanium dioxide and yellow iron oxide. The black ink contains the following inactive ingredients: black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac and strong ammonia solution.

CLINICAL PHARMACOLOGY

Introduction

Wilson's disease (hepatolenticular degeneration) is an autosomal inherited metabolic defect resulting in an inability to maintain a near-zero balance of copper. Excess copper accumulates possibly because the liver lacks the mechanism to excrete free copper into the bile. Hepatocytes store excess copper but when their capacity is exceeded copper is released into the blood and is taken up into extrahepatic sites. This condition is treated with a low copper diet and the use of chelating agents that bind copper to facilitate its excretion from the body.

Clinical Summary

Forty-one patients (18 male and 23 female) between the ages of 6 and 54 with a diagnosis of Wilson's disease and who were intolerant of d-penicillamine were treated in two separate studies with trientine HCl. The dosage varied from 450 to 2,400 mg per day. The average dosage required to achieve an optimal clinical response varied between 1,000 mg and 2,000 mg per day. The mean duration of trientine HCl therapy was 48.7 months (range 2 to 164 months). Thirty-four of the 41 patients improved, 4 had no change in clinical global response, 2 were lost to follow-up and one showed deterioration in clinical condition. One of the patients who improved while on therapy with trientine HCl experienced a recurrence of the symptoms of systemic lupus erythematosus which had appeared originally during therapy with penicillamine. Therapy with trientine HCl was discontinued. No other adverse reactions, except iron deficiency, were noted among any of these 41 patients.

One investigator treated 13 patients with trientine HCl following their development of intolerance to d-penicillamine. Retrospectively, he compared these patients to an additional group of 12 patients with Wilson's disease who were both tolerant of and controlled with d-penicillamine therapy, but who failed to continue any copper chelation therapy. The mean age at onset of disease of the latter group was 12 years as compared to 21 years for the former group. The trientine HCl group received d-penicillamine for an average of 4 years as compared to an average of 10 years for the non-treated group.

Various laboratory parameters showed changes in favor of the patients treated with trientine HCl. Free and total serum copper, SGOT and serum bilirubin all showed mean increases over baseline in the untreated group which were significantly larger than with the patients treated with trientine HCl. In the 13 patients treated with trientine HCl, previous symptoms and signs relating to d-penicillamine intolerance disappeared in 8 patients, improved in 4 patients, and remained unchanged in one patient. The neurological status in the trientine hydrochloride group was unchanged or improved over baseline, whereas in the untreated group, 6 patients remained unchanged and 6 worsened. Kayser-Fleischer rings improved significantly during trientine HCl treatment.

The clinical outcome of the two groups also differed markedly. Of the 13 patients on therapy with trientine HCl (mean duration of therapy 4.1 years; range 1 to 13 years), all were alive at the data cutoff date, and in the non-treated group (mean years with no therapy 2.7 years; range 3 months to 9 years), 9 of the 12 died of hepatic disease.

Chelating Properties

Preclinical Studies

Studies in animals have shown that trientine HCl has cupriuretic activities in both normal and copper-loaded rats. In general, the effects of trientine HCl on urinary copper excretion are similar to those of equimolar doses of penicillamine, although in one study they were significantly smaller.

Human Studies

Renal clearance studies were carried out with penicillamine and trientine HCl on separate occasions in selected patients treated with penicillamine for at least one year. Six-hour excretion rates of copper were determined off treatment and after a single dose of 500 mg of penicillamine or 1.2 g of trientine HCl. The mean urinary excretion rates of copper were as follows:

No. of Patients	Single Dose Treatment	Basal Excretion Rate (mcg Cu ++ /6hr)	Test-dose Excretion Rate (mcg Cu ++ /6hr)
6	Trientine, 1.2 g	19	234
4	Penicillamine, 500 mg	17	320

In patients *not* previously treated with chelating agents, a similar comparison was made:

No. of Patients	Single Dose Treatment	Basal Excretion Rate (mcg Cu ++ /6hr)	Test-dose Excretion Rate (mcg Cu ++ /6hr)
8	Trientine, 1.2 g	71	1,326
7	Penicillamine, 500 mg	68	1,074

These results demonstrate that trientine HCl is effective as a cupriuretic agent in patients with Wilson's disease although on a molar basis it appears to be less potent or less effective than penicillamine. Evidence from a radio-labelled copper study indicates that the different cupriuretic effect between these two drugs could be due to a difference in selectivity of the drugs for different copper pools within the body.

Pharmacokinetics

Data on the pharmacokinetics of trientine HCl are not available. Dosage adjustment recommendations are

based upon clinical use of the drug (see **DOSAGE AND ADMINISTRATION**).

INDICATIONS AND USAGE

Trientine HCl capsules are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine HCl capsules is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine HCl capsules and penicillamine cannot be considered interchangeable. Trientine HCl capsules should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.

Unlike penicillamine, trientine HCl capsules are not recommended in cystinuria or rheumatoid arthritis. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine HCl capsules was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment.

Trientine HCl capsules are not indicated for treatment of biliary cirrhosis.

CONTRAINDICATIONS

Hypersensitivity to this product.

WARNINGS

Patient experience with trientine HCl is limited (see **CLINICAL PHARMACOLOGY**). Patients receiving trientine HCl should remain under regular medical supervision throughout the period of drug administration. Patients (especially women) should be closely monitored for evidence of iron deficiency anemia.

PRECAUTIONS

General

There are no reports of hypersensitivity in patients who have been administered trientine HCl for Wilson's disease. However, there have been reports of asthma, bronchitis and dermatitis occurring after prolonged environmental exposure in workers who use trientine HCl as a hardener of epoxy resins. Patients should be observed closely for signs of possible hypersensitivity.

Information for Patients

Patients should be directed to take trientine HCl on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other drug, food, or milk. The capsules should be swallowed whole with water and should not be opened or chewed. Because of the potential for contact dermatitis, any site of exposure to the capsule contents should be washed with water promptly. For the first month of treatment, the patient should have his temperature taken nightly, and he should be asked to report any symptom such as fever or skin eruption.

Laboratory Tests

The most reliable index for monitoring treatment is the determination of free copper in the serum, which equals the difference between quantitatively determined total copper and ceruloplasmin-copper. Adequately treated patients will usually have less than 10 mcg free copper/dL of serum.

Therapy may be monitored with a 24-hour urinary copper analysis periodically (i.e., every 6 to 12 months). Urine must be collected in copper-free glassware. Since a low copper diet should keep copper absorption down to less than one milligram a day, the patient probably will be in the desired state of negative copper balance if 0.5 to 1 milligram of copper is present in a 24-hour collection of urine.

Drug Interactions

In general, mineral supplements should not be given since they may block the absorption of trientine HCl. However, iron deficiency may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilson's disease. If necessary, iron may be given in short courses, but since iron and trientine HCl each inhibit absorption of the other, two hours should elapse between administration of trientine HCl and iron.

It is important that trientine HCl be taken on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other drug, food, or milk. This permits maximum absorption and reduces the likelihood of inactivation of the drug by metal binding in the gastrointestinal tract.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Data on carcinogenesis, mutagenesis, and impairment of fertility are not available.

Pregnancy

Pregnancy Category C. Trientine HCl was teratogenic in rats at doses similar to the human dose. The frequencies of both resorptions and fetal abnormalities, including hemorrhage and edema, increased while fetal copper levels decreased when trientine hydrochloride was given in the maternal diets of rats. There are no adequate and well-controlled studies in pregnant women. Trientine HCl should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when trientine HCl is administered to a nursing mother.

Pediatric Use

Controlled studies of the safety and effectiveness of trientine HCl in pediatric patients have not been conducted. It has been used clinically in pediatric patients as young as 6 years with no reported adverse experiences.

Geriatric Use

Clinical studies of trientine HCl did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience is insufficient to determine differences in responses between the elderly and younger patients. In general, dose selection should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS

Clinical experience with trientine HCl has been limited. The following adverse reactions have been reported in a clinical study in patients with Wilson's disease who were on therapy with trientine HCl: iron deficiency, systemic lupus erythematosus (see **CLINICAL PHARMACOLOGY**). In addition, the following adverse reactions have been reported in marketed use: dystonia, muscular spasm, myasthenia gravis.

Trientine HCl is not indicated for treatment of biliary cirrhosis, but in one study of 4 patients treated with trientine HCl for primary biliary cirrhosis, the following adverse reactions were reported: heartburn; epigastric pain and tenderness; thickening, fissuring and flaking of the skin; hypochromic microcytic anemia; acute gastritis; aphthoid ulcers; abdominal pain; melena; anorexia; malaise; cramps; muscle pain; weakness; rhabdomyolysis. A causal relationship of these reactions to drug therapy could

not be rejected or established.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

There is a report of an adult woman who ingested 30 grams of trientine HCl without apparent ill effects. No other data on overdose are available.

DOSAGE AND ADMINISTRATION

Systemic evaluation of dose and/or interval between dose has not been done. However, on limited clinical experience, the recommended initial dose of trientine HCl capsules is 500 to 750 mg/day for pediatric patients and 750 to 1,250 mg/day for adults given in divided doses two, three or four times daily. This may be increased to a maximum of 2,000 mg/day for adults or 1,500 mg/day for pediatric patients age 12 or under.

The daily dose of trientine HCl capsules should be increased only when the clinical response is not adequate or the concentration of free serum copper is persistently above 20 mcg/dL. Optimal long-term maintenance dosage should be determined at 6 to 12 month intervals (see **PRECAUTIONS, Laboratory Tests**).

It is important that trientine HCl capsules be given on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other drug, food, or milk. The capsules should be swallowed whole with water and should not be opened or chewed.

HOW SUPPLIED

Trientine HCl capsules, USP, **250 mg**, are supplied as hard gelatin caramel colored capsules printed with black ink: "TRIENTINE" on cap and "250 mg" on body. They are available as follows:

Bottles of 100: NDC 69238-1545-1

STORAGE

Keep container tightly closed.

Store refrigerated at 2° to 8°C (36° to 46°F).

Distributed by:

Amneal Pharmaceuticals LLC

Bridgewater, NJ 08807

Made in Portugal

Rev. 09-2017-00

PRINCIPAL DISPLAY PANEL

NDC 69238-1545-1

Trientine HCl Capsules, USP

250 mg



Rx only
100 Capsules



Each capsule contains:
250 mg of trientine hydrochloride, USP

USUAL DOSAGE: See accompanying package insert.

Store refrigerated at 2° to 8°C (36° to 46°F).
Keep container tightly closed.

This is a bulk package and not intended for dispensing.

Dispense in a tight container.

Distributed by: **Amneal Pharmaceuticals LLC**
Bridgewater, NJ 08807

Made in Portugal

Rev. 09-2017-00



0.75" x 2"
Non-Varnish Area
for Lot No. & Exp. date



TRIENTINE HYDROCHLORIDE

trientine capsule, gelatin coated

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:69238-1545
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
TRIENTINE HYDRO CHLORIDE (UNII: HC3NX54582) (TRIENTINE - UNII:SJ76 Y07H5F)	TRIENTINE HYDROCHLORIDE	250 mg

Inactive Ingredients

Ingredient Name	Strength
STEARIC ACID (UNII: 4ELV7Z65AP)	
FERROSO FERRIC OXIDE (UNII: XM0M87F357)	
GELATIN (UNII: 2G86QN327L)	
FERRIC OXIDE RED (UNII: 1K09F3G675)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
FERRIC OXIDE YELLOW (UNII: EX438O2MRT)	
POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
SHELLAC (UNII: 46N107B71O)	
AMMONIA (UNII: 5138Q19F1X)	
BUTYL ALCOHOL (UNII: 8PJ61P6TS3)	
ISOPROPYL ALCOHOL (UNII: ND2M416302)	
WATER (UNII: 059QF0KO0R)	
ALCOHOL (UNII: 3K9958V90M)	

Product Characteristics

Color	BROWN (caramel)	Score	no score
Shape	CAPSULE	Size	19mm
Flavor		Imprint Code	TRIENTINE;250mg
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69238-1545-1	100 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2019	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA210619	02/08/2019	

Labeler - Amneal Pharmaceuticals NY LLC (123797875)

